Printer Friendly

SMITHKLINE BEECHAM LAUNCHES PAXIL

 PHILADELPHIA, Feb. 1 /PRNewswire/ SmithKline Beecham's (NYSE: SBH) Paxil (paroxetine hydrochloride) for the treatment of depression is now available in pharmacies, the company announced today.
 The launch comes four weeks after approval from the U.S. Food and Drug Administration.
 Paxil is indicated for the treatment of depression. In addition, it has been shown to be effective for the prevention of depressive relapse during long-term treatment.
 Paxil is a member of a class of antidepressants called selective serotonin reuptake inhibitors (SSRIs). This class includes Prozac (fluoxetine) and Zoloft (sertraline), and as a class these agents offer significant advantages over older antidepressants. There are differences between the SSRIs, and Paxil may have some features that prove beneficial in the clinic, such as a well defined dosing regimen and pharmacokinetic profile that should allow the clinician greater flexibility.
 Additionally, Paxil is priced lower than both Prozac and Zoloft. The average wholesale price of Paxil is about 3 percent less than Zoloft's and about 15 percent less than Prozac's.
 SmithKline Beecham -- one of the world's leading healthcare companies -- discovers, develops, manufactures and markets human and animal pharmaceuticals, over-the-counter medicines, and clinical laboratory testing services.
 /delval/
 -0- 2/1/93
 /CONTACT: Sharyn M. Arnold of SmithKline Beecham, 215-751-7074/
 (SBH)


CO: SmithKline Beecham; U.S. Food and Drug Administration ST: Pennsylvania IN: MTC SU: PDT

LJ -- PH017 -- 1300 02/01/93 11:00 EST
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Feb 1, 1993
Words:229
Previous Article:PENNSYLVANIA PROGRAM WILL PROVIDE DRUGS FOR AIDS AND SCHIZOPHRENIA
Next Article:1992 - THE WORLD WITNESSED CHANGING TIMES, GENERATIONS, ADMINISTRATIONS, And Mourned the Death of Superman 1993 - BLACK HISTORY MONTH. NOW WITNESS...
Topics:


Related Articles
SMITHKLINE BEECHAM'S PAXIL GETS ADVISORY COMMITTEE OK; EXPERT PANEL RECOMMENDS MARKETING APPROVAL FOR NEW ANTIDEPRESSANT
FDA APPROVES SMITHKLINE BEECHAM'S PAXIL FOR U.S. MARKETING FOR THE TREATMENT OF DEPRESSION
SMITHKLINE BEECHAM PLEDGES $5 MILLION OF NEW ANTIDEPRESSANT TO BENEFIT NEEDY PATIENTS
SMITHKLINE BEECHAM'S PAXIL WINS DIANA AWARD FOR BEST NEW PRODUCT INTRODUCTION; SB HONORED FOR SECOND YEAR IN A ROW
SMITHKLINE BEECHAM'S PAXIL ADDED TO MEDI-CAL FORMULARY
SMITHKLINE BEECHAM LAUNCHES VECTAVIR IN THE U.K., NEW TREATMENT FOR HERPES LABIALIS
SmithKline Beecham's Denavir(TM), First Topical Antiviral Cream For Treatment of Cold Sores, Cleared for Marketing by FDA
Paxil(R) Shows Effectiveness With Fewer Side Effects In Treating Depressed Patients With Ischemic Heart Disease
Scios to Co-Promote SmithKline Beecham's Paxil
Scios to Co-Promote SmithKline Beecham's Paxil

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters